Search research articles
Contact Us
Filters
Showing results (31-40 of 86) with videos related to
Page
of 9
Sort By:
Journal of Medical Economics
|
February 17, 2016
Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US
David Bruhn, Alan A Martin, Ruben Tavares, et al.
Journal of Medical Economics
|
February 23, 2024
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England
Tariq H Iqbal, Nicholas Kennedy, Anjan Dhar, et al.
Advances in Therapy
|
November 27, 2012
A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin
Richard F Pollock, Bradley H Curtis, Jayne Smith-Palmer, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 6, 2017
Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden
Johan Jendle, Åsa Ericsson, Barnaby Hunt, et al.
Journal of Comparative Effectiveness Research
|
January 16, 2019
A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada
Richard F Pollock, Kirsi Norrbacka, Chris Cameron, et al.
Applied Health Economics and Health Policy
|
March 12, 2018
Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation
William J Valentine, Kate Van Brunt, Kristina S Boye, et al.
Advances in Therapy
|
August 10, 2022
A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose
Richard F Pollock, Philip A Kalra, Paul R Kalra, et al.
Journal of Medical Economics
|
April 11, 2022
Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose
Shanlian Hu, Limin Liu, Richard F Pollock, et al.
Applied Health Economics and Health Policy
|
September 14, 2011
A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland
Kurt Lippuner, Richard F Pollock, Jayne Smith-Palmer, et al.
Advances in Therapy
|
April 14, 2019
Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
Pierre Johansen, Barnaby Hunt, Neeraj N Iyer, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 86) with videos related to
Sort By:
Page
of 9
Journal of Medical Economics
|
February 17, 2016
Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US
David Bruhn, Alan A Martin, Ruben Tavares, et al.
Journal of Medical Economics
|
February 23, 2024
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England
Tariq H Iqbal, Nicholas Kennedy, Anjan Dhar, et al.
Advances in Therapy
|
November 27, 2012
A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin
Richard F Pollock, Bradley H Curtis, Jayne Smith-Palmer, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 6, 2017
Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden
Johan Jendle, Åsa Ericsson, Barnaby Hunt, et al.
Journal of Comparative Effectiveness Research
|
January 16, 2019
A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada
Richard F Pollock, Kirsi Norrbacka, Chris Cameron, et al.
Applied Health Economics and Health Policy
|
March 12, 2018
Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation
William J Valentine, Kate Van Brunt, Kristina S Boye, et al.
Advances in Therapy
|
August 10, 2022
A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose
Richard F Pollock, Philip A Kalra, Paul R Kalra, et al.
Journal of Medical Economics
|
April 11, 2022
Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose
Shanlian Hu, Limin Liu, Richard F Pollock, et al.
Applied Health Economics and Health Policy
|
September 14, 2011
A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland
Kurt Lippuner, Richard F Pollock, Jayne Smith-Palmer, et al.
Advances in Therapy
|
April 14, 2019
Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
Pierre Johansen, Barnaby Hunt, Neeraj N Iyer, et al.
Page
of 9